To uncover the clinical signals and factors associated with the persistence of high levels of NAb after hospital discharge, we compared those two groups of COVID-19 recovered individuals across various guidelines. (26.5% vs. 16.3%, = 0.033), and presented with diabetes comorbidity (25.2% vs. 12.2%, = 0.004); high blood urea (median (IQR): 4.8 (3.7, 6.1) vs. 3.9 (3.5, 5.4) mmol/L; = 0.017); CRP (31.6 (4.0, 93.7) vs. 16.3 (2.7, 51.4) mg/L; = 0.027); PCT (0.08 (0.05, 0.17) vs. 0.05 (0.03, 0.09) ng/mL; = 0.001); SF (838.5 (378.2, 1533.4) DUSP1 vs. 478.5 (222.0, 1133.4) g/L; = 0.035); and fibrinogen (5.1 (3.8, 6.4) vs. 4.5 (3.5, 5.7) g/L; = 0.014) levels, but low SpO2 levels (96.0 VcMMAE (92.0, 98.0) vs. 97.0 (94.0, 98.0)%; = 0.009). The predictive model based on Gaussian combination models, displayed an average accuracy of 0.7117 in one of the 8191 formulas, and ROC analysis showed an AUC value of 0.715 (0.657C0.772), and specificity and level of sensitivity were 72.5% and 67.3%, respectively. In conclusion, we found that several factors at admission can contribute to the higher level of NAbs in individuals after discharge, and constructed a predictive model for long-term NAb levels, which can provide guidance for medical treatment and monitoring. Keywords: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus (SARS-CoV-2), neutralizing antibody (NAb), diabetes, corticosteroids 1. Intro The severe acute respiratory syndrome coronavirus VcMMAE type 2 (SARS-CoV-2) pandemic offers caused havoc around the world. Immunity after recovery from Coronavirus disease 2019 (COVID-19), is currently a subject of conversation in attempts to combat the pandemic. Persistent high levels of protecting antibodies in individuals who recover from COVID-19 are thought to guard against reinfection from your SARS-CoV-2 [1,2]. However, due to variations in infection conditions, treatment regimens, and individual immune status, the production and period of protecting antibodies often tend to become poles apart among recovered individuals. Several studies possess confirmed the protecting antibodies, especially neutralizing antibodies (NAbs) against SARS-CoV-2, rapidly decrease within a few months after recovery from the disease, risking some individuals at the edge of reinfection [3,4,5,6]. Interestingly, the pace of decay and decrease in protecting antibodies is definitely highly heterogeneous across individuals [7,8]. The levels of neutralizing antibodies six months, or even more, after recovery from COVID-19, remain high in a few individuals, which can help them respond rapidly to prevent reinfection. A study that investigated recovered individuals who have been infected with SARS-CoV-2 in the early phases, possess reported that at least 90% of convalescents retained positive NAbs and SARS-CoV-2-specific T-cell reactions, 6 and 12 months after the disease onset, although varying in degree [9]. In addition to the immune memory characteristics of survivors, factors during early hospitalization associated with the persistence of high levels of NAb in individuals six months or longer after recovery, are still infancy and, thus, worth exploring. Given the sociable and economic implications of the pandemic, estimating the effectiveness and period VcMMAE of long-term protecting antibodies after discharge from private hospitals, based on early signals, is attractive but challenging. It can also help appropriate medical treatment and care and attention in the future. In this study, we investigate the demographic and medical factors at admission, or the early stage of individuals hospitalization, associated with long term high levels of NAb against SARS-CoV-2. Data for individuals that recovered from COVID-19 for at least six months were analyzed. Additionally, a model for predicting the long-term levels of NAb against COVID-19 after recovery was also constructed using the Gaussian combination model. This model helps to guidebook treatment strategies and monitor reactions to COVID-19 therapy, and infer long-term antibody protecting efficacy from the earliest indications of hospitalization. 2. Materials and Methods 2.1. Study Human population A total of 306 individuals who recovered from COVID-19 were enrolled in this study. As described in the previous study [10], these individuals.